182 related articles for article (PubMed ID: 34953602)
21. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
[TBL] [Abstract][Full Text] [Related]
22. Mutation signatures to Pan-Cancer Atlas: Investigation of the genomic landscape of muscle-invasive bladder cancer.
Cooley LF; Glaser AP; Meeks JJ
Urol Oncol; 2022 Jul; 40(7):279-286. PubMed ID: 32122728
[TBL] [Abstract][Full Text] [Related]
23. The Rate of Prostatic Involvement in Men Treated With Radical Cystectomy for Muscle Invasive Bladder Cancer.
Royal-Preyra B; Cury FL; Katib Y; Monsoor M; Brimo F; Kassouf W; Souhami L
Pract Radiat Oncol; 2023; 13(1):e68-e72. PubMed ID: 35901948
[TBL] [Abstract][Full Text] [Related]
24. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.
Groenendijk FH; de Jong J; Fransen van de Putte EE; Michaut M; Schlicker A; Peters D; Velds A; Nieuwland M; van den Heuvel MM; Kerkhoven RM; Wessels LF; Broeks A; van Rhijn BW; Bernards R; van der Heijden MS
Eur Urol; 2016 Mar; 69(3):384-8. PubMed ID: 25636205
[TBL] [Abstract][Full Text] [Related]
25. High-precision Bladder Cancer Irradiation in the Elderly: Clinical Results for a Plan-of-the-day Integrated Boost Technique with Image Guidance Using Lipiodol Markers.
Beulens AJW; van der Toorn PP; de Wildt MJ; Scheepens WA
Eur Urol Oncol; 2019 Feb; 2(1):39-46. PubMed ID: 30929845
[TBL] [Abstract][Full Text] [Related]
26. Cross-species oncogenomics offers insight into human muscle-invasive bladder cancer.
Wong K; Abascal F; Ludwig L; Aupperle-Lellbach H; Grassinger J; Wright CW; Allison SJ; Pinder E; Phillips RM; Romero LP; Gal A; Roady PJ; Pires I; Guscetti F; Munday JS; Peleteiro MC; Pinto CA; Carvalho T; Cota J; Du Plessis EC; Constantino-Casas F; Plog S; Moe L; de Brot S; Bemelmans I; Amorim RL; Georgy SR; Prada J; Del Pozo J; Heimann M; de Carvalho Nunes L; Simola O; Pazzi P; Steyl J; Ubukata R; Vajdovich P; Priestnall SL; Suárez-Bonnet A; Roperto F; Millanta F; Palmieri C; Ortiz AL; Barros CSL; Gava A; Söderström ME; O'Donnell M; Klopfleisch R; Manrique-Rincón A; Martincorena I; Ferreira I; Arends MJ; Wood GA; Adams DJ; van der Weyden L
Genome Biol; 2023 Aug; 24(1):191. PubMed ID: 37635261
[TBL] [Abstract][Full Text] [Related]
27. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
Teo MY; Mota JM; Whiting KA; Li HA; Funt SA; Lee CH; Solit DB; Al-Ahmadie H; Milowsky MI; Balar AV; Pietzak E; Dalbagni G; Bochner BH; Ostrovnaya I; Bajorin DF; Rosenberg JE; Iyer G
Eur Urol; 2020 Dec; 78(6):907-915. PubMed ID: 32753285
[TBL] [Abstract][Full Text] [Related]
28. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA
Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065
[TBL] [Abstract][Full Text] [Related]
29. Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine.
Tsukahara S; Shiota M; Takamatsu D; Nagakawa S; Matsumoto T; Kiyokoba R; Yagi M; Setoyama D; Noda N; Matsumoto S; Hayashi T; Contreras-Sanz A; Black PC; Inokuchi J; Kohashi K; Oda Y; Uchiumi T; Eto M; Kang D
Sci Rep; 2022 May; 12(1):8535. PubMed ID: 35595780
[TBL] [Abstract][Full Text] [Related]
30. Mutational Landscape of Bladder Cancer in Mexican Patients:
Pérez-Montiel MD; Cerrato-Izaguirre D; Sánchez-Pérez Y; Diaz-Chavez J; Cortés-González CC; Rubio JA; Jiménez-Ríos MA; Herrera LA; Scavuzzo A; Meneses-García A; Hernández-Martínez R; Vaca-Paniagua F; Ramírez A; Orozco A; Cantú-de-León D; Prada D
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674608
[TBL] [Abstract][Full Text] [Related]
31. Deep Learning Predicts Molecular Subtype of Muscle-invasive Bladder Cancer from Conventional Histopathological Slides.
Woerl AC; Eckstein M; Geiger J; Wagner DC; Daher T; Stenzel P; Fernandez A; Hartmann A; Wand M; Roth W; Foersch S
Eur Urol; 2020 Aug; 78(2):256-264. PubMed ID: 32354610
[TBL] [Abstract][Full Text] [Related]
32. A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy.
de Jong FC; Iflé IG; van der Made AC; Kooper D; de Jong JJ; Franckena M; Zuiverloon TCM; van Criekinge W; Incrocci L; Zwarthoff EC; Boormans JL
Eur Urol Open Sci; 2024 Apr; 62():131-139. PubMed ID: 38496820
[TBL] [Abstract][Full Text] [Related]
33. Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle-invasive bladder cancer.
Gurung PM; Veerakumarasivam A; Williamson M; Counsell N; Douglas J; Tan WS; Feber A; Crabb SJ; Short SC; Freeman A; Powles T; Hoskin PJ; West CM; Kelly JD
Int J Cancer; 2015 Feb; 136(3):709-20. PubMed ID: 24917520
[TBL] [Abstract][Full Text] [Related]
34. CD19
Jiang Q; Fu Q; Chang Y; Liu Z; Zhang J; Xu L; Zhu Y; Wang Y; Zhang W; Xu J
Cancer Immunol Immunother; 2019 Jan; 68(1):45-56. PubMed ID: 30259082
[TBL] [Abstract][Full Text] [Related]
35. Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: May neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes?
Hurmuz P; Ozyigit G; Kilickap S; Esen CSB; Akdogan B; Ozen H; Akyol F
Urol Oncol; 2021 Jun; 39(6):368.e19-368.e29. PubMed ID: 33189528
[TBL] [Abstract][Full Text] [Related]
36. A TP53-based immune prognostic model for muscle-invasive bladder cancer.
Li H; Lu H; Cui W; Huang Y; Jin X
Aging (Albany NY); 2020 Dec; 13(2):1929-1946. PubMed ID: 33323544
[TBL] [Abstract][Full Text] [Related]
37. A comprehensive molecular characterization of the 8q22.2 region reveals the prognostic relevance of OSR2 mRNA in muscle invasive bladder cancer.
Uysal D; Kowalewski KF; Kriegmair MC; Wirtz R; Popovic ZV; Erben P
PLoS One; 2021; 16(3):e0248342. PubMed ID: 33711044
[TBL] [Abstract][Full Text] [Related]
38. Lymphovascular invasion and the presence of more than three tumors are associated with poor outcomes of muscle-invasive bladder cancer after bladder-conserving therapies.
Zhang M; Tao R; Zhang C; Shen Z
Urology; 2010 Oct; 76(4):902-7. PubMed ID: 20709377
[TBL] [Abstract][Full Text] [Related]
39. Clinical and histopathological features of bladder cancer following radiotherapy for prostate cancer: A comparative study.
Scherñuk J; González MI; Vecchio F; Alfieri AG; Tobia IP; Tejerizo JC; Favre GA
Urol Oncol; 2022 Nov; 40(11):492.e1-492.e6. PubMed ID: 35945111
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer: A retrospective multicenter study.
Orré M; Latorzeff I; Fléchon A; Roubaud G; Brouste V; Gaston R; Piéchaud T; Richaud P; Chapet O; Sargos P
PLoS One; 2017; 12(4):e0174978. PubMed ID: 28384195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
